Justin Eyquem

This study uses deep learning and physics-based modeling to engineer a CD27 variant that improves the efficacy of CD70-targeting CAR T-cells across multiple cancer models.

This paper develops a virus-like particle-based system for CRISPR gene editing and screening in primary human myeloid cells, identifying TNFAIP3 as a key regulator of inflammatory polarization.

This study shows dendritic cells enhance CAR T cell persistence in irradiated tumors by antigen-dressing and stimulating CAR T cells through chimeric receptors.

This paper develops a non-viral BCMA CAR-T therapy using CRISPR and 1XX signaling, showing improved safety, potency, and persistence in multiple myeloma.

The paper uses local gene editing in mouse tumor models to discover a novel fibroblast state and its impact on the tumor microenvironment.

Combining TCE therapy with IL-2 enhances TCE efficacy in aggressive small-cell lung cancer and melanoma models with low target antigen density through T cell clonal replacement and CD8+ effector T cell differentiation.

The paper shows that TCRs from Tregs are more effective than Tconv TCRs in driving pTreg differentiation, with distinct phenotypes based on antigen type.

This study uses base-editing to inactivate a missense mutation in A20ZF7, enhancing CAR-T cell efficacy by reducing exhaustion and improving anti-tumor responses.

This paper develops a genome engineering workflow for primary human NK cells using CRISPR/Cas9 and AAV6 to integrate and disrupt genes, enhancing anti-tumor function through targeted CAR expression.

This paper performs in vivo CRISPR screens in human T cells to identify genetic modifiers of T cell function in solid tumors, finding P2RY8-G13 and GNAS as key regulators.

This paper develops dual-antigen targeting CAR-T cells against CD70 and active integrin β2 to overcome AML antigen heterogeneity and reduce off-tumor toxicity.

This study uses programmable microparticles to enhance CAR-T cell expansion beyond physiological limits by rewiring signaling pathways.

This paper introduces PERC, a method for efficient CRISPR editing in primary human immune cells and HSPCs using a peptide reagent, achieving over 90% editing efficiency without specialized equipment.

This study shows that SYK negatively regulates NK cell signaling and that its deletion enhances CD19-CAR NK cell efficacy in cancer immunotherapy.

This study introduces hydroporation as a scalable and efficient method for delivering CAR-T cells, achieving higher yields and viability compared to traditional methods.

This paper designs novel transcription factors using evolutionary principles to generate T cell states with enhanced functionality.

This paper develops a method to efficiently reprogram T cells at multiple loci using SEED-Selection, achieving high purity for single and combined gene edits.

The paper develops a non-viral method using hybrid ssDNA repair templates to improve genome engineering in primary human cells, achieving high knock-in efficiency and cell yields for disease modeling and cell therapy.